New Alzheimer’s drugs may have limited population-level impact, researchers warn
Cambridge scientists question whether recently approved amyloid immunotherapy treatments for Alzheimer’s disease will significantly reduce the condition’s burden, citing concerns about efficacy, safety, and health system challenges.
